Bay Space biotech Guardant Well being introduced the business launch of its early-detection colon most cancers check on Monday, marking the newest twist in an escalating race to identify most cancers sooner and extra precisely.
The corporate’s check, often known as Defend, is out there to adults 45 and older who aren’t updated with present screening pointers, don’t have signs, and are at common danger of colon most cancers. Defend is a lab-developed check, which means that it hasn’t been accepted by the Meals and Drug Administration and that every pattern (a couple of tablespoon of blood) should be despatched to Guardant’s lab.
